FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029168684> ?p ?o ?g. }

• W2029168684 endingPage "945" @default.
• W2029168684 startingPage "945" @default.
• W2029168684 abstract "Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost Robert D Fechtner1, Paul Harasymowycz2, Donald R Nixon3, Steven D Vold4, Fiaz Zaman5, Julia M Williams6, David A Hollander61Glaucoma Division, University of Medicine and Dentistry New Jersey, Newark, NJ, USA; 2University of Montreal, Montreal, QC, Canada; 3Royal Victoria Hospital, Barrie, ON, Canada; 4Boozman-Hof Regional Eye Clinic, Rogers, AR, USA; 5Houston Eye Associates, Houston, TX, USA; 6Allergan Inc, Irvine, CA, USAObjective: To evaluate the additive intraocular pressure (IOP)-lowering efficacy and safety of fixed-combination brimonidine 0.2%/timolol 0.5% compared with timolol 0.5% at peak and trough effect when used as therapy adjunctive to latanoprost 0.005% in patients with glaucoma or ocular hypertension who require additional IOP lowering.Methods: In this prospective, randomized, multicenter, investigator-masked, parallel-group study, patients were treated with latanoprost monotherapy for at least four weeks prior to baseline. At baseline on latanoprost, patients with IOP ≥21 mmHg in at least one eye were randomized to twice-daily fixed brimonidine-timolol (n = 102) or timolol (n = 102), each adjunctive to latanoprost for 12 weeks. IOP was measured at 8 am and 10 am at baseline, week 6, and week 12 and evaluated in the per protocol population. The primary efficacy endpoint was peak IOP lowering at 10 am, week 12. Safety measures included adverse events.Results: Baseline mean IOP was similar at 10 am in the treatment groups (brimonidine-timolol 23.4 mmHg; timolol 23.0 mmHg). The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001). Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a ≥20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12. Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients. Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.Conclusion: Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension. Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.Keywords: brimonidine, drug combinations, glaucoma, intraocular pressure, ocular hypertension, timolol" @default.
• W2029168684 created "2016-06-24" @default.
• W2029168684 creator A5008779045 @default.
• W2029168684 creator A5010307105 @default.
• W2029168684 creator A5011901496 @default.
• W2029168684 creator A5025756764 @default.
• W2029168684 creator A5035033005 @default.
• W2029168684 creator A5058804038 @default.
• W2029168684 creator A5068301392 @default.
• W2029168684 date "2011-07-01" @default.
• W2029168684 modified "2023-09-27" @default.
• W2029168684 title "Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost" @default.
• W2029168684 cites W192974951 @default.
• W2029168684 cites W1963493193 @default.
• W2029168684 cites W1974179473 @default.
• W2029168684 cites W1977695585 @default.
• W2029168684 cites W2047327741 @default.
• W2029168684 cites W2062882436 @default.
• W2029168684 cites W2064249983 @default.
• W2029168684 cites W2067542801 @default.
• W2029168684 cites W2070099990 @default.
• W2029168684 cites W2073959877 @default.
• W2029168684 cites W2077729265 @default.
• W2029168684 cites W2110897487 @default.
• W2029168684 cites W2118638775 @default.
• W2029168684 cites W2140594570 @default.
• W2029168684 cites W2146861004 @default.
• W2029168684 cites W2147093603 @default.
• W2029168684 cites W2163315500 @default.
• W2029168684 cites W3025522717 @default.
• W2029168684 doi "https://doi.org/10.2147/opth.s19999" @default.
• W2029168684 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3141858" @default.
• W2029168684 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21792284" @default.
• W2029168684 hasPublicationYear "2011" @default.
• W2029168684 type Work @default.
• W2029168684 sameAs 2029168684 @default.
• W2029168684 citedByCount "7" @default.
• W2029168684 countsByYear W20291686842012 @default.
• W2029168684 countsByYear W20291686842014 @default.
• W2029168684 countsByYear W20291686842016 @default.
• W2029168684 countsByYear W20291686842019 @default.
• W2029168684 countsByYear W20291686842020 @default.
• W2029168684 countsByYear W20291686842021 @default.
• W2029168684 crossrefType "journal-article" @default.
• W2029168684 hasAuthorship W2029168684A5008779045 @default.
• W2029168684 hasAuthorship W2029168684A5010307105 @default.
• W2029168684 hasAuthorship W2029168684A5011901496 @default.
• W2029168684 hasAuthorship W2029168684A5025756764 @default.
• W2029168684 hasAuthorship W2029168684A5035033005 @default.
• W2029168684 hasAuthorship W2029168684A5058804038 @default.
• W2029168684 hasAuthorship W2029168684A5068301392 @default.
• W2029168684 hasBestOaLocation W20291686841 @default.
• W2029168684 hasConcept C118487528 @default.
• W2029168684 hasConcept C126322002 @default.
• W2029168684 hasConcept C141071460 @default.
• W2029168684 hasConcept C168563851 @default.
• W2029168684 hasConcept C197934379 @default.
• W2029168684 hasConcept C2776521421 @default.
• W2029168684 hasConcept C2776727336 @default.
• W2029168684 hasConcept C2776740260 @default.
• W2029168684 hasConcept C2778073030 @default.
• W2029168684 hasConcept C2778190193 @default.
• W2029168684 hasConcept C2778527774 @default.
• W2029168684 hasConcept C2781092963 @default.
• W2029168684 hasConcept C71924100 @default.
• W2029168684 hasConceptScore W2029168684C118487528 @default.
• W2029168684 hasConceptScore W2029168684C126322002 @default.
• W2029168684 hasConceptScore W2029168684C141071460 @default.
• W2029168684 hasConceptScore W2029168684C168563851 @default.
• W2029168684 hasConceptScore W2029168684C197934379 @default.
• W2029168684 hasConceptScore W2029168684C2776521421 @default.
• W2029168684 hasConceptScore W2029168684C2776727336 @default.
• W2029168684 hasConceptScore W2029168684C2776740260 @default.
• W2029168684 hasConceptScore W2029168684C2778073030 @default.
• W2029168684 hasConceptScore W2029168684C2778190193 @default.
• W2029168684 hasConceptScore W2029168684C2778527774 @default.
• W2029168684 hasConceptScore W2029168684C2781092963 @default.
• W2029168684 hasConceptScore W2029168684C71924100 @default.
• W2029168684 hasLocation W20291686841 @default.
• W2029168684 hasLocation W20291686842 @default.
• W2029168684 hasLocation W20291686843 @default.
• W2029168684 hasLocation W20291686844 @default.
• W2029168684 hasOpenAccess W2029168684 @default.
• W2029168684 hasPrimaryLocation W20291686841 @default.
• W2029168684 hasRelatedWork W2010755453 @default.
• W2029168684 hasRelatedWork W2014785256 @default.
• W2029168684 hasRelatedWork W2022054938 @default.
• W2029168684 hasRelatedWork W2027345384 @default.
• W2029168684 hasRelatedWork W2065005955 @default.
• W2029168684 hasRelatedWork W2085699621 @default.
• W2029168684 hasRelatedWork W2128225127 @default.
• W2029168684 hasRelatedWork W2128476364 @default.
• W2029168684 hasRelatedWork W2170698422 @default.
• W2029168684 hasRelatedWork W2612340917 @default.
• W2029168684 isParatext "false" @default.
• W2029168684 isRetracted "false" @default.
• W2029168684 magId "2029168684" @default.
• W2029168684 workType "article" @default.